Vical Completes Enrollment For Vaccine Trial

Vical Incorporated (NASDAQ:VICL) finished enrollment of 225 subjects for their Phase 2 therapeutic bivalent vaccine trial on herpes simplex virus type 2.

As quoted in the press release:

The randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of the vaccine in healthy adults aged 18 to 50 years with symptomatic genital HSV-2 infection and is being conducted at 15 U.S. clinical sites. Subjects are evaluated for lesion recurrences over a 12-month period following a 4-dose vaccination series. The study is powered to show a reduction in annualized lesion recurrence rate, an endpoint which is clinically meaningful in this chronic disease setting because it provides information on the number of recurrences over time.

“A therapeutic vaccine is an important and promising new approach for reducing genital lesion recurrences because of its potential ability to boost immunity against HSV-2,” said Dr. John Kriesel, Associate Professor and infectious disease specialist at the University of Utah School of Medicine and one of the investigators in the Phase 2 trial. “Genital herpes afflicts one in six people in the United States and can be emotionally debilitating. A therapeutic vaccine would give patients a new treatment for this chronic disease.”

“We are pleased with the outstanding support we have received from our investigators and site staff, as the completion of the target enrollment of this Phase 2 trial represents an important milestone for this program,” said Dr. Mammen “Anza” Mammen, Vical’s Vice President, Clinical Vaccines. “We continue to follow these subjects and anticipate release of top-line efficacy results during the second quarter of 2018.”

HSV-2 is a sexually transmitted virus that causes a persistent infection that can result in painful genital lesions, as well as intermittent virus shedding placing sexual partners at risk of infection. Infection with HSV-2 also significantly increases the risk of acquiring the HIV-1 virus from HIV-infected sexual partners. There is no FDA approved vaccine for HSV-2. Vical’s investigational therapeutic bivalent vaccine encodes two full-length, HSV-2 antigens, glycoprotein D and VP11/12 tegument protein (also referred to as UL46) and is formulated with our patented adjuvant Vaxfectin®.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.


Leave a Reply